NEW YORK (GenomeWeb news) – Aurora Health Care of Milwaukee, Wis., will work with Celera to offer genetic cardiovascular tests under a new collaboration, Celera said yesterday.

Celera said that the agreement makes Aurora "the first health care provider in Wisconsin and one of the first in the nation" to offer the company's test for a variant in the KIF6 gene that has been shown to indicate increased risk for heart disease.

The company said that untreated carriers of the KIF6 gene variant have a 50 percent to 55 percent greater risk of heart attacks than non-carriers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.